99 related articles for article (PubMed ID: 11295088)
1. Pharmacokinetics of intraoperative intrapleural cisplatin chemotherapy of various osmolarities in cases of esophageal cancer.
Katano K; Tsujitani S; Maeta M; Fukuda K; Oka S; Hisamitsu K; Ikeguchi M; Kaibara N
Oncol Rep; 2001; 8(3):605-9. PubMed ID: 11295088
[TBL] [Abstract][Full Text] [Related]
2. Hypotonic intrapleural cisplatin chemotherapy as treatment for pleural carcinomatosis in an experimental model.
Katano K; Tsujitani S; Saito H; Ikeguchi M; Maeta M; Kaibara N
Anticancer Res; 1997; 17(6D):4547-52. PubMed ID: 9494566
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of hypotonic cisplatin chemotherapy administered into the peritoneal and the pleural cavities in experimental model.
Katano K; Tsujitani S; Oka S; Saito H; Gomyo Y; Kondo A; Ikeguchi M; Maeta M; Kaibara N
Anticancer Res; 2000; 20(3A):1603-7. PubMed ID: 10928078
[TBL] [Abstract][Full Text] [Related]
4. Administration in a hypotonic solution is preferable to dose escalation in intraperitoneal cisplatin chemotherapy for peritoneal carcinomatosis in rats.
Tsujitani S; Oka A; Kondo A; Katano K; Oka S; Saito H; Ikeguchi M; Maeta M; Kaibara N
Oncology; 1999 Jul; 57(1):77-82. PubMed ID: 10394129
[TBL] [Abstract][Full Text] [Related]
5. Hepatic arterial infusion of cisplatin diluted in hypotonic 25 g/l glucose solution administered in balloon-occluded hepatic artery: experimental rationale and clinical pilot study.
Isambert N; Correia M; Cercueil JP; Zanetta S; Osmak L; Flesch M; Krause D; Coudert B; Fargeot P; Bedenne L; Chauffert B
J Exp Clin Cancer Res; 2001 Jun; 20(2):183-8. PubMed ID: 11484972
[TBL] [Abstract][Full Text] [Related]
6. Improvement in intraperitoneal intraoperative cisplatin exposure based on pharmacokinetic analysis in patients with ovarian cancer.
Royer B; Delroeux D; Guardiola E; Combe M; Hoizey G; Montange D; Kantelip JP; Chauffert B; Heyd B; Pivot X
Cancer Chemother Pharmacol; 2008 Mar; 61(3):415-21. PubMed ID: 17503047
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days.
Vouillamoz-Lorenz S; Buclin T; Lejeune F; Bauer J; Leyvraz S; Decosterd LA
Anticancer Res; 2003; 23(3C):2757-65. PubMed ID: 12926110
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of cis-diamminedichloroplatinum (II) given as low-dose and high-dose infusions.
Kurihara N; Kubota T; Hoshiya Y; Otani Y; Ando N; Kumai K; Kitajima M
J Surg Oncol; 1996 Jun; 62(2):135-8. PubMed ID: 8649040
[TBL] [Abstract][Full Text] [Related]
9. Hypotonic cisplatin treatment for carcinomatous pleuritis found at thoracotomy in patients with lung cancer. In vitro experiments and preliminary clinical results.
Ichinose Y; Hara N; Ohta M; Asoh H; Yano T; Maeda K; Yagawa K
J Thorac Cardiovasc Surg; 1993 Jun; 105(6):1041-6. PubMed ID: 8388966
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites.
Verschraagen M; Boven E; Ruijter R; van der Born K; Berkhof J; Hausheer FH; van der Vijgh WJ
Clin Pharmacol Ther; 2003 Aug; 74(2):157-69. PubMed ID: 12891226
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients.
Specenier PM; Ciuleanu T; Latz JE; Musib LC; Darstein CL; Vermorken JB
Cancer Chemother Pharmacol; 2009 Jul; 64(2):233-41. PubMed ID: 19011858
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacokinetic analysis of intra-peritoneal administration of cisplatin].
Terashima M; Ikeda K; Takagane A; Sasaki N; Abe K; Araya M; Nishizuka S; Yonezawa H; Irinoda T; Nakaya T; Oyama K; Saito K
Gan To Kagaku Ryoho; 1997 Sep; 24(12):1859-62. PubMed ID: 9382551
[TBL] [Abstract][Full Text] [Related]
13. [Tissue platinum distribution and the effect following intra-arterial injection of cisplatin to metastatic liver cancer--a case report].
Nemoto H; Takeuchi S; Yoshizawa Y; Uemichi O; Sasaya S; Yamaguchi M; Makuuchi M; Midorikawa T; Sanada Y; Kumada K; Takizawa K
Gan To Kagaku Ryoho; 2001 Aug; 28(8):1149-53. PubMed ID: 11525035
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacologic markers predictive of neutropenia chemically induced by cisplatin (CDDP)].
Gory-Delabaere G; Cupissol D; Brès J; Gau F; Constans B; Nouguier-Soulé J
J Soc Biol; 1999; 193(1):49-55. PubMed ID: 10851556
[TBL] [Abstract][Full Text] [Related]
15. Application of cisplatin as intraoperative hyperthermic peritoneal lavage (IHPL) in patients with locally advanced gastric cancer: analysis of pharmacokinetics and of nephrotoxicity.
Kern W; Braess J; Kotschofsky M; Samel S; Becker H; Hiddemann W; Schleyer E
Anticancer Res; 2002; 22(5):3099-102. PubMed ID: 12530050
[TBL] [Abstract][Full Text] [Related]
16. The administration of hypotonic intraperitoneal cisplatin during operation as a treatment for the peritoneal dissemination of gastric cancer.
Tsujitani S; Fukuda K; Saito H; Kondo A; Ikeguchi M; Maeta M; Kaibara N
Surgery; 2002 Jan; 131(1 Suppl):S98-104. PubMed ID: 11821794
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of liposomal cisplatin (lipoplatin) in combination with 5-FU in patients with advanced head and neck cancer: first results of a phase III study.
Jehn CF; Boulikas T; Kourvetaris A; Possinger K; Lüftner D
Anticancer Res; 2007; 27(1A):471-5. PubMed ID: 17352269
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study.
Stathopoulos GP; Boulikas T; Vougiouka M; Deliconstantinos G; Rigatos S; Darli E; Viliotou V; Stathopoulos JG
Oncol Rep; 2005 Apr; 13(4):589-95. PubMed ID: 15756428
[TBL] [Abstract][Full Text] [Related]
19. [Intrapleural hypotonic cisplatin treatment for carcinomatous pleuritis in cases of primary lung cancer].
Yokouchi H; Nagase H; Ide Y; Ota H; Maruyama K; Okada K; Yanagisawa T; Mukai R; Murata K; Kinuta M; Tamai M
Gan To Kagaku Ryoho; 2009 Nov; 36(12):2124-6. PubMed ID: 20037344
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant chemotherapy with 5-fluorouracil and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma.
Lee J; Lee KE; Im YH; Kang WK; Park K; Kim K; Shim YM
Ann Thorac Surg; 2005 Oct; 80(4):1170-5. PubMed ID: 16181835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
